Effects of glucagon-like peptide 1 (9-36) on endothelial nitric oxide synthase in human umbilical vein endothelial cells

National Medical Journal of China

Volumn 92, Issue 42, 2012, Pages 3008-3011

  Ding, Li ^a   Zhang, Jin ^a   Zhang, Shao Wei ^b   Zhao, Wen Zhou ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Diabetes mellitus, type 2; Endothelial nitric oxide synthase; Glucagon like peptide 1; Human umbilical vein endothelial cells

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

CELLS, CULTURED; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDES; PHOSPHORYLATION;

EID: 84872229624     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.42.016     Document Type: Article

References (12)

1. Tomas E, Wood J A, Stanojevic V, et al. Glucagon-like peptide-1 (9-36) amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Diabetes Obes Metab, 2011, 13:26-33.
2. Tomas E, Stanojevic V, Habener J F. GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res, 2010, 42:657-662.
3. Ban K, Kim K H, Cho C K, et al. Glucagon-like peptide (GLP)-1 (9-36) amide-mediated cytoprotection is blocked byexendin (9-39) yet does not require the known GLP-1 receptor. Endocrinology, 2010, 151: 1520-1531.
4. Drucker D J, Nauck M A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368:1696-1705.
5. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab, 2009, 23:443-452.
6. Deacon C F, Johnsen A H, Hoist J J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 1995, 80:952-957.
7. Højberg P V, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improve the insulin response to glucagon-like peptide -1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia, 2009, 52: 199-207.
8. Connell P, Walshe T, Ferguson G, et al. Elevated glucose attenuates agonist- and flow-stimulated endothelial nitric oxide synthase activity in microvascular retinal endothelial cells. Endothelium, 2007, 14:17-24.
9. Yuen D Y, Dwyer R M, Matthews V B, et al. Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes, 2009, 58: 1086-1095.
10. 2011, 91:1413-1416.
11. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic: blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab, 2011, 13:81-88.
12. Buse J B, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009, 374:39-47.